CareDx (CDNA) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
CareDx Reports Preliminary Second Quarter 2016 Financial Results
August 10, 2016 4:01 PM EDTBRISBANE, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the second quarter ended June 30, 2016.
Recent highlights:
Achieved total revenue for the second quarter of 2016 of $10.7 million AlloMap® revenues were $7.2 million in the quarterAlloMap patient results volumes in the U.S. were up by 12% year-over-yearOlerup® revenues contributed $3.4 million in the second quarter Advanced AlloSure®... More